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Abstract
ADA is an enzyme implicated in purine metabolism, and is critical to ensure normal immune function. Its congenital deficit
leads to severe combined immunodeficiency (SCID). ADA binding to adenosine receptors on dendritic cell surface enables
T-cell costimulation through CD26 crosslinking, which enhances T-cell activation and proliferation. Despite a large body of
work on the actions of the ecto-enzyme ADA on T-cell activation, questions arise on whether ADA can also modulate
dendritic cell maturation. To this end we investigated the effects of ADA on human monocyte derived dendritic cell biology.
Our results show that both the enzymatic and non-enzymatic activities of ADA are implicated in the enhancement of CD80,
CD83, CD86, CD40 and CCR7 expression on immature dendritic cells from healthy and HIV-infected individuals. These ADA-
mediated increases in CD83 and costimulatory molecule expression is concomitant to an enhanced IL-12, IL-6, TNF-a,
CXCL8(IL-8), CCL3(MIP1-a), CCL4(MIP-1b) and CCL5(RANTES) cytokine/chemokine secretion both in healthy and HIV-infected
individuals and to an altered apoptotic death in cells from HIV-infected individuals. Consistently, ADA-mediated actions on
iDCs are able to enhance allogeneic CD4 and CD8-T-cell proliferation, globally yielding increased iDC immunogenicity.
Taken together, these findings suggest that ADA would promote enhanced and correctly polarized T-cell responses in
strategies targeting asymptomatic HIV-infected individuals.
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Introduction
Adenosine deaminase (ADA, EC 3.5.4.4) is a key enzyme in the
purine pathway catalyzing the irreversible deamination of
adenosine or 29-deoxyadenosine to inosine or 29-deoxyinosine
and ammonia. ADA’s function is essential in maintaining an
immune response as patients with ADA deficiency suffer from
SCID, a rare inherited metabolic disorder that causes lymphope-
nia and immunodeficiency [1,2] due to the accumulation of toxic
substrates [3] and excessive adenosine receptor activation [4].
ADA is released into the extracellular medium by immune cells
where the enzyme can bind to certain membrane proteins such as
CD26 [5–7] and adenosine receptors A1 [8], A2B [9] and A2A [10].
CD26 is a T-cell-activation marker molecule that has dipeptidyl-
peptidase enzymatic activity. Physiologically, this activity regulates
the actions of several peptides, including chemokines [11].
Adenosine receptors are members of the G protein coupled
receptor family. A1 is negatively coupled to adenylate cyclase,
while A2A and A2B can activate this same enzyme through the Gs
protein subunit. The latter leads to an increase in cAMP levels,
which may account for the adenosine mediated anti-inflammatory
effects on T-cells, neutrophils or antigen presenting cells [12].
Thus, ADA is expressed as an ecto-enzyme with relevant
physiological roles in the immune synapse [13,14]. On one hand,
the enzymatic activity of ADA reduces adenosine levels available
for stimulation of adenosine receptors expressed on the T-cell
surface contributing to immune regulation [7,15,16]. On the other
hand, ADA delivers costimulatory signals to T-cells through CD26
crosslinking [17]. By acting as a bridge between A2B adenosine
receptors on dendritic cells (DCs) and CD26 on T-cells [13], ADA
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acts as a costimulatory molecule in DC-T-cell cocultures
enhancing T-cell proliferation, Th-1/pro-inflammatory cytokine
secretion [13], and T-CD4+ cell activation, memory, and Foxp3+
generation in both healthy and HIV-infected subjects [18].
Although HIV gp120 envelope protein disrupts the ADA-CD26
interaction [19], possibly contributing to the immunodeficiency
[20], ADA is still able to enhance autologous T-cell proliferation
against inactivated-HIV presentation by DC in individuals under
HAART [21], suggesting a beneficial role for ADA on improving
HIV-specific T-cell responses in those individuals [22].
While ADA actions on T-cells have been extensively studied, its
actions on human DC are still largely unknown, despite the pivotal
role of these cells on the immunological synapse and T-cell
activation. In fact, DCs are the most potent antigen presenting
cells (APC), critical in the initiation and control of protective
immune responses [23,24]. Immature dendritic cells (iDCs) are
widely spread among peripheral tissues, where they actively scan
the environment to detect any invading pathogen or foreign
antigen. Towards this end, pathogen associated molecular patterns
(PAMPS), nucleotides, inflammatory cytokines or cell damage
activate a complex DC maturation program consisting of the up-
regulation of maturation markers such as CD83, costimulatory
(such as CD80, CD86 and CD40) and HLA molecules, the
activation of CCR7 expression-induced migration to secondary
lymph-nodes and the secretion of T-cell polarizing cytokines, in
a process set to efficiently activate antigen-specific T-cells [25]. In
contrast, in the absence of alarm signals, self-antigens are
presented to T-cells in the absence of or in limited costimulation,
Table 1. Clinical information of patients with HIV-1.
Patients Receiving HAART (n=11)
Sex Age VL* T CD4 T CD4 Nadir T CD8 Progression
cells/mL % cells/mL % cells/mL %
M 48 ,DL 582 28 255 28 882 42 NC
M 68 ,DL 565 24 277 14 1354 66 NC
M 33 ,DL 1075 34 396 16 1458 45 VC
M 40 ,DL 666 42 537 30 458 21 NC
M 63 ,DL 539 23 266 20 1174 51 NC
M 40 ,DL 671 22 243 19 1456 47 NC
F 51 ,DL 342 11 332 10 2533 79 VC
F 59 ,DL 1245 41 185 35 1435 48 NC
F 44 ,DL 625 37 274 28 809 48 NC
M 35 2,7 764 45 365 26 673 40 NC
M 37 2,7 1193 31 783 29 2297 59 VC
Mean 2,7 751,5 30,7 355,7 23,2 1320,8 49,6
SD 291,4 10,3 170,5 7,8 641,4 14,9
Patients Not Receiving HAART (n=11)
Sex Age VL* T CD4 T CD4 Nadir T CD8 Progression
cells/mL % cells/mL % cells/mL %
M 60 ,DL 420 16 420 16 1182 45 VC
M 65 1,6 512 26 504 28 874 44 EC
F 54 1,9 540 20 451 19 854 52 EC
M 48 2,1 876 31 823 30 1355 48 VC
M 36 3,1 576 32 197 30 1332 59 VC
M 34 3,2 519 25 406 29 1148 55 NC
M 31 3,4 480 30 480 30 76 48 VC
M 35 3,4 660 22 452 16 1368 46 NC
F 47 3,4 844 47 702 44 638 35 EC
M 35 3,5 880 40 867 36 1582 48 N/A
M 41 3,5 664 30 537 17 979 44 NC
Mean 2,9 633,7 29,0 530,8 26,8 1035,3 47,6
SD 0,8 165,7 8,9 195,7 9,0 421,2 6,3
*VL is expressed as log viral copies/ml.
NC: Non controller.
VC: Viremic Controller.
EC: Elite Controller.
doi:10.1371/journal.pone.0051287.t001
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which results in tolerance, either by T-cell apoptosis, anergy or
regulatory T-cell (Treg) development in a process driven by
inhibitory receptors such as PD-1 or CTLA-4 [26] and suppressive
mediators such as IL-10, TGF-b or adenosine [27–29]. These
unique and versatile properties of DCs makes them a valuable tool
for therapeutic vaccination purposes such as in HIV [30,31],
cancer [32,33] or tolerogenic approaches [34]. Therefore, it is
important to know the role played by ADA on the biology of DCs.
Since it has been observed that DCs are able to arise from
monocytes in vivo [35,36], monocyte-derived DCs are a good
model for in vitro studies [37]. In this study we have addressed the
role of ADA on the expression of costimulatory molecules, on
cytokine and chemokine secretion, on the immunogenicity,
migration and viability of human monocyte-derived DC from
healthy or HIV-infected donors. Four novel observations derive
from this study: First, ADA enhances DCs costimulatory molecule
expression. Second, ecto-ADA actions on iDCs are able to
increase the secretion of both pro-inflammatory cytokines and
chemokines that are known to promote Th-1 immune responses.
Third, we establish that both the enzymatic and enzymatic-
independent role of ADA participate in ADA-induced effects.
Finally, ADA globally enhances the immunogenicity of human
DCs, a process that results in improved CD4+ T-cell proliferation
after alloantigen presentation. These results demonstrate that
ADA can lead to an increased mature DC status; a property that
can be harnessed to improve the outcome of immune responses to
chronic infections such as HIV.
Materials and Methods
Sampling and Study Population
Blood samples were obtained by venipuncture from the
antecubital vein using EDTA-treated vacutainers (Becton Dick-
inson, Mountain View, CA, USA) and were processed immedi-
ately after extraction. Healthy control volunteers (n = 25) and
HIV-1-infected individuals (n = 22) were included in the study.
The study received the approval of the Institutional Committee of
Ethics and Clinical Investigation and all individuals gave informed
written consent. The characteristics of HIV- infected subjects are
shown in Table 1.
Antibodies and Reagents
FITC-conjugated mAbs against HLA-DR, HLA-ABC, CD4,
CD14, CD19, CD25, CD45RA and IgG-c1 isotype-matched
control, PE-conjugated mAbs against HLA-DR, CD1a, CD11c,
CD14, CD19, CD25, CD40, CD45RO, CD56 and IgG-c1
isotype-matched control, PerCP-conjugated mAbs against CD3,
CD4 and IgG-c1 isotype-matched control and PE-Cy7-conjugated
mAb against CCR7 from Becton Dickinson Biosciences (Erembo-
degem-Aalst, Belgium); PE-conjugated mAbs against CD80,
CD83 and CD86 from Coulter-Immunotech Diagnostic (Mar-
seille, France); PE-conjugated mAb against CD209 from
eBioscience (California, USA). Human-specific mAb against
CD26, TA5.9-CC1-4C8 were used as previously indicated
[13,19,20].
ADA Preparation and Activity Determination
ADA from calf intestine (Roche Diagnostic Inc, Mannheim,
Germany) was desalted by passage through a PD-10 column
(Amersham Biosciences, Cerdanyola, Spain) and its enzymatic
activity was evaluated by adenosine deamination measured as
decreases in absorbance at 265 nm as previously reported [38]. To
obtain ADA without enzymatic activity, desalted ADA was treated
with HgCl2 as described previously [8] and passed again through
a PD-10 column to eliminate remaining HgCl2. The enzymatic
activity of Hg2+-treated ADA (ADA-Hg) was completely abolished.
The possibility of LPS contamination in the ADA preparations
was addressed by boiling the ADA preparation for 10 min before
its addition to iDCs cultures. This process completely removed
ADA’s ability to induce phenotypic changes in iDCs (data not
shown).
Generation of Monocyte-derived DCs
Monocyte-derived DCs were obtained as described previously
[13,18,39]. Human PBMC were obtained immediately after blood
extraction using the standard Ficoll gradient method. To obtain
monocytes, PBMC were incubated for 2 h at 37uC in a humid
atmosphere of 5% CO2 in 75 cm
2 plastic flasks with DC-medium,
consisting of serum free XVIVO-15 medium (Bio-Whittaker,
Walkersville, MD, USA) supplemented with 1% autologous
serum, 50 mg/ml gentamycin (Braun B., Melsungen, Germany),
2.5 mg/ml fungizone (Bristol-Myers Squibb, Munchen, Germany)
and, in the case of HIV-infected individuals, with 1 mM
zidovudine (Retrovir from GlaxoSmithKline, Madrid, Spain) to
avoid possible replication of endogenous HIV-1. To obtain
immature DCs (iDCs) adherent monocytes were washed four
times with pre-warmed serum free XVIVO-10 medium (Bio-
Whittaker) and cultured during 5 days in DC-medium, supple-
mented at days 0 and 2 with human recombinant IL-4 and GM-
CSF (1000 UI/ml, each) (Prospec-Tany Technogene LTD,
Rehovot, Israel). The purity and immunophenotype were assessed
by flow cytometry and was found to be similar to previously
reported [13,18,39]. At day 5 of differentiation, iDCs were washed
4 times with XVIVO-10 media, counted and 5?6105 cells/ml
distributed in 12.5 cm2 plastic flasks with fresh DC-medium
supplemented with IL-4 and GM-CSF. To obtain ADA-treated
DCs or fully mature DCs (mDCs), 2 mM ADA or 10 ml/ml of
cytokine maturation cocktail were added, and cultured for two
additional days. This cytokine maturation cocktail contains TNF-
a, IL-6 (1000 UI/ml each, Strathmann-Biotec AG), IL-1b
(300 UI/ml, Strathmann Biotec AG) and PGE2 (1 mg/ml, Pfizer,
Madrid, Spain).
T-cell Isolation, Cocultures and Proliferation Assays
As a source of T-cell-enriched population, non-adherent PBMC
(see above) were washed four times with XVIVO-10 medium and
collected for further coculture experiments as described before
[13,18]. To measure T-cell proliferation, 107 cells/ml were stained
with 5 mM CFSE using the CellTrace CFSE proliferation kit
(Molecular Probes, Paisley,UK) as indicated by the manufacturer’s
protocol.
Autologous or allogeneic cocultures were performed in 96-well
round bottom plates, containing non-treated or treated iDCs (104
cells/well) and fresh CFSE stained T-cells (2?6105 cells) in a final
volume of 200 ml of in XVIVO-10 media. T-cell proliferation was
assessed by flow cytometry after 7 days of coculture in a humidified
atmosphere with 5% CO2 at 37uC.
Cytokine and Chemokine Secretion Measurement
iDCs, ADA-treated iDCs or mDCs (5?6105 cell/ml) were
cultured in DC-medium and the secretion of cytokines and
chemokines was measured in the supernatants after 48 h of
culture. Multiplex Luminex assays (Cytokine Human 25-Plex
Panel, Invitrogen, Carlsbad, CA, USA) were performed following
the manufacturer instructions. The following 25 mediators were
tested: Eotaxin, GM-CSF, IL-1b, IL-1RA, IL-2, IL-2R, IL-4, IL-
5, IL-6, IL-7, CXCL8(IL-8), IL-10, IL-12p40/p70, IL-13, IL-15,
IL-17, IFN-a, IFN-c, CXCL10(IP-10), CCL2(MCP-1),
ADA Enhances the Immunogenicity of Dendritic Cells
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CXCL9(MIG), CCL3(MIP1-a), CCL4(MIP-1b),
CCL5(RANTES) and TNF-a.
Chemotaxis Assay
DCs migration towards CCL19 or CCL21 chemokines (from
PeproTech, London, UK) was measured in a 96-plate transwell
chemotaxis chambers (Corning Costar, Cambridge, MA, USA),
using a polycarbonate filter of 5 mm pore size as previously
reported [40]. Briefly, 150 ml of recombinant human CCL19
(300 ng/ml) or recombinant human CCL21 (250 ng/ml) or
medium alone were placed in the lower wells. Upper wells were
loaded with 50 ml of XVIVO-15 medium containing 2.5?6104
iDCs, ADA-treated iDCs or mDCs. Each condition was set up
in duplicates. The complete chamber was kept in a humidified
atmosphere with 5% CO2 at 37uC for 3 h. Thereafter, cell
suspensions in the upper well were removed and cells that had
migrated through the filter to the lower wells were counted by
flow cytometry for 1 min. Values were given as percentage of
migrated cells 6 SEM in relation to the initial cell input.
Flow Cytometry
Cells were collected, washed with PBS and incubated 30 min at
4uC with PBS containing 10% rabbit serum and 0.1% NaN3 prior
30 min incubation (4uC) with primary labeled antibodies. When
CCR7 staining was performed, cells were incubated with PBS
containing 5% BSA for 30 min at room temperature prior staining
with CCR7-labeled monoclonal antibody for 30 min at 4uC. Cells
were washed with PBS and 10,000 to 50,000 events were collected
on a FACsCAN or a FACsCANTO flow cytometer (Becton
Dickinson Biosciences Erembodegem-Aalst, Belgium). Data was
analyzed with FlowJo software (Tree Star, Inc. Ashland, OR,
USA). The expression of iDCs immunophenotype (CD32,
CD142, CD192, CD562, HLA-DR+, HLA-ABC+, CD80low,
CD83low, CD86+, CD1a+, CD11c+, CD40+, CD45RO+,
CD45RA2) was addressed and the percentage of positive cells
and the geometric mean fluorescence intensity was measured. DC
and T-cell populations were selected by forward and side light-
scatter parameters.
Cell Death Assay
iDCs, ADA-treated iDCs and mDCs were carefully washed
with XVIVO-15 medium after 48 h cell culture in DC-medium.
Cells (2?105) were resuspended in 200 ml of XVIVO-15 media and
incubated with 40 nM of the potentiometric mitochondrial probe
DIOC6 (Molecular Probes; Invitrogen, Carlsbad, California, USA)
and 10 ml of propidium iodide (Sigma-Aldrich, St. Louis, MO,
USA) for 1 h at 37uC. Samples were then acquired in
a FACsCANTO instrument (BD). A minimum of 10,000 events
of every sample were collected and analyzed on FlowJo software.
After gating on DCs population by Forward and Side parameters,
apoptotic and necrotic cells were identified by their low DIOC6
fluorescence [41] plus the absence or presence of propidium
Iodide staining.
Statistical Analysis
Graphs were plotted using the GraphPad Prism 5.0 software
(GraphPad Software, Inc., San Diego, California, USA).
Quantitative variables were analyzed using medians and IQRs.
The non-parametric Mann Whitney U-test for unpaired data or
the Wilcoxon signed rank test for paired data were used when
comparing two groups. For multiple comparisons, Kruskal-
Wallis test followed by Dunns post-test was used. For all the
tests used, a two tailed P value ,0.05 was considered
statistically significant.
Results
ADA enhances the expression of costimulatory molecules in
iDCsTo study the influence of ADA on the phenotype of DCs, we
first investigated the effect of ADA on the expression of
costimulatory molecules by flow cytometry. Immature monocyte-
derived DCs (iDCs) from healthy or HIV-infected donors were
cultured in the absence or in the presence of ADA for 48 h, and
the expression of CD83, CD80 and CD86 was compared with the
expression detected in mature DCs (mDCs) obtained from the
same donors after a cytokine-PGE2 maturation cocktail stimula-
tion [42]. Different doses of ADA were tested, choosing 2 mM as
the lowest dose at which significant ADA effects were observed
(Fig. S1 A and B). When iDCs were treated with ADA, a consistent
and statistically significant (P,0.001) upregulation of CD83 (Fig. 1
A and B) and CD80 (Fig. 1 C and D) was observed, both in
healthy and in HIV-infected donors. As expected, mDCs showed
a marked increase in the expression of CD83 and CD80 (Fig. 1 A
and C). When assessing CD86 expression (Fig. 1 E and F), all DCs
expressed CD86 (.95% cells were positive for this marker) but
culturing iDCs in the presence of ADA resulted in a statistically
significant increase in the CD86 geometric mean, which was seen
in healthy donors (P,0.05) as well as in HIV-infected individuals
(P,0.001) (Fig. 1 F). Again, mDCs expressed a higher CD86
geometric mean than its immature counterparts. CD83, CD80
and CD86 are classically considered maturation markers [43], and
their upregulation suggests that ADA is potentiating DC
maturation. The coordinated upregulation of costimulatory and
HLA molecules on the surface of DCs is a characteristic feature of
maturing DCs [43], thus, we next sought to examine the ADA
effect on HLA expression in the same experimental settings as
above. No statistically significant changes in the geometric mean of
HLA-DR (Fig. 2 A and B) or HLA-ABC (Fig. 2 C and D) were
obtained in either healthy nor in HIV-infected individuals when
their iDCs were cultured in the presence of ADA. In contrast,
cytokine maturation of DCs clearly increased the HLA-DR and
HLA-ABC geometric means (Fig. 2 A and C). Both ADA
treatment and cytokine maturation cocktail failed to affect the
percentage of cells expressing other monocyte-derived DCs
markers such as CD11c (90% positive) or CD14 (,5% positive).
The failure of ADA to induce a clear upregulation of HLA
molecules indicates that ADA does not promote a full maturation
process but a preferential enhancement of costimulatory mole-
cules. To address the latter, the ADA effect on the expression of
CD40, another costimulatory marker, was measured. All iDCs
expressed CD40 (.95% cells were positive on this marker). A
moderate and significant (p,0.05) increase in CD40 geometric
mean was observed when iDCs from healthy donors were treated
with ADA (Fig. 2 E and F). A tiny increase in CD40 geometric
mean was noticeable when iDCs from HIV-infected individuals
were treated with ADA, although this effect was not consistent on
every patient tested due to a high inter-individual variability (Fig. 2
F). In contrast, a clear increase in geometric mean was observed
both in healthy and HIV individuals in mDCs (Fig. 2 E).
Considering that CD83, CD80, CD86 and CD40 are important
for delivering the appropriate secondary signals to T-cells [43,44]
the ADA-mediated up-regulation of these markers indicates that
ADA may increase the costimulatory potential of iDCs. Given the
heterogeneity of the different HIV-infected individuals (table 1) we
sought to determine whether differences could be observed on
iDCs by classifying patients according to their clinical parameters,
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including CD4+ or CD8+ cell counts, viral load, HAART
treatment or disease progression (controller vs non controller).
This analysis shows that iDCs from patients with detectable
viremia have increased CD80 while reduced CD83 expression
compared to patients with undetectable viremia (Fig. S2 B). No
other major differences were found on this analysis. We further
tested whether the ADA effects on costimulatory markers
expression might correlate with any clinical parameter from these
patients. Interestingly, ADA-mediated effects on CD80 expression
did correlate with the patients’ viral load (Fig. S3 A), but no other
major correlations were found.
ADA Enhances Th-1/pro-inflammatory Cytokine and
Chemokine Secretion
Eliciting the appropriate cytokine and chemokine expression
pattern to each invading pathogen is critical to ensure a correctly
polarized and efficient immune response [25]. To investigate
whether ADA was able to enhance DC cytokine and chemokine
release and to characterize the specific molecules involved, we
analyzed the expression of 25 cytokines and chemokines in culture
supernatants from non-treated and ADA-treated iDCs. iDCs from
either healthy or HIV-infected individuals were cultured in the
absence or in the presence of ADA or with the maturation
cocktail. After 48 h supernatants were collected for further
analysis. ADA addition to iDCs cultures resulted in a consistent
enhancement in the release of a specific group of Th-1/pro-
inflammatory cytokines and chemokines both in healthy and in
HIV donors (Fig. 3). IL-12, whose secretion is pivotal in regulating
Th-1 polarization, was augmented 2-fold in the presence of ADA
when compared to iDCs in both healthy and HIV-infected
individuals. When the pro-inflammatory cytokines were addressed,
a striking 10-fold up-regulation of IL-6 was found, whereas a less
consistent increase in TNF-a (2.5 median in-fold) was seen (Fig. 3).
It must be noted that IL-1b which is often found together with IL-
6 and TNF-a under inflammatory stimuli, was not detected in our
iDC cultures in any donor, suggesting that a very specific effect
was triggered. Low, yet measurable levels (40–50 pg/ml) of the
antiviral IFN-a cytokine were detected in iDCs, but were not
increased by ADA (Fig. S1 C). When chemoattractant mediators
were analyzed in the supernatants, a clear and significant increase
in CXCL8, CCL3, CCL4 and CCL5 was observed in healthy
donors and also in HIV-infected individuals (Fig. 3). The ADA-
mediated increase on these latter three CCL chemokines (b-
chemokines) is relevant to HIV pathogenesis since potent HIV-
inhibitory activities are associated to these mediators [45]. In
addition, ADA induced a less prominent but noticeable increase in
other chemokines such as CCL2 (Fig. 3) or CXCL9 (1.35 median
in-fold, Fig. S1). Importantly, the cytokine and chemokine profile
enhanced by ADA is very similar to the one observed for mDCs
(Fig. S1). It is also remarkable that in our culture conditions no
measurable levels of eotaxin, IL-5, IL-7, IL-13, IL-15, IL-17 and
CXCL10 were detected (data not shown).
ADA Enzymatic–dependent and Independent Activities
Contribute to its Effects on iDCs
Both adenosine deamination and CD26 binding are reported to
have important roles on the immune system [7,14]. Thus, we
sought to delineate the particular contribution of these activities on
the ADA-mediated effects on iDCs. To address this question, we
blocked the enzymatic activity of ADA via inhibition with HgCl2
(ADA-Hg). ADA-Hg is unable to degrade adenosine while
retaining its receptor binding capability [8]. iDCs were then
cultured in the absence or presence of ADA or ADA-Hg. As
expected, ADA led to an upregulation of CD83 and CD80
expression on all donors tested (Fig. 4 A and B). By contrast, ADA-
Hg decreased the ADA-mediated up-regulation of CD83 and
CD80 in a median of 0.7 and 0.8 in-fold respectively (Fig. 4 A).
Despite this reduction, ADA-Hg was still able to induce a notice-
able increase in CD80 and CD83 expression compared to non-
treated iDCs (Fig. 4 A), indicating that a mechanism other than
the enzymatic activity must also be involved. Since the presence of
ADA on cell membranes has classically been associated to CD26
expression in many cell types [5,46,47] and CD26 is also expressed
in human iDCs [13], the participation of CD26 on ADA-mediated
effects on iDCs was investigated. To address this, the mAb TA5.9,
which is directed against the ADA-binding epitope on CD26, was
used. When iDCs had been previously pre-incubated with TA5.9,
the ADA-mediated upregulation of CD83 and CD80 was reduced
by 0.46 and 0.64 in-folds respectively suggesting an important role
for ADA binding to CD26 in the ADA-mediated increase in CD86
and CD80 expression (Fig. 4 B). Our next goal was to address the
role of ADA enzymatic activity and CD26 binding on cytokine
and chemokine release. iDCs cultured in the presence of ADA-Hg
have a decreased secretion of IL-12, CCL2, CCL4 and slightly
CCL3 (Fig. 4 C) while TNF-a secretion was not significantly
modified and IL-6 secretion was enhanced under these conditions
(Fig. 4 C). When the mAb TA5.9 was used in the same
experimental settings, no significant effect could be seen on IL-
12, TNF-a or CCL3 secretion, while IL-6, CCL2 and CCL4 were
slightly decreased (Fig. 4 C). Interestingly, neither the ADA-
mediated changes in CXCL8 and CCL5 secretion were affected
by ADA-Hg or TA5.9 (results not shown), suggesting these require
a mechanism independent of CD26 or adenosine levels. Taken
together, these results suggest that both the enzymatic activity and
binding to CD26 contribute to the global ADA mediated effects
observed, since the abrogation of one of these mechanisms alone
does not abolish all the ADA effects.
ADA Enhances the DCs Capacity to Stimulate Allogeneic
T-cells
The ADA-induced enhancement of costimulatory molecules
expression and Th-1/pro-inflammatory mediators release on
iDCs, suggested that ADA could render iDCs more immunogenic
by improving antigen presentation. To address this question, iDCs
were cultured in the absence or presence of ADA or with
maturating cocktail during 48 h, strictly washed, and cocultured
with allogeneic CFSE-stained T-cells or autologous CFSE-stained
T-cells as a negative control. Proliferation of both CD4+ and
CD8+ T-cell subsets was quantified. As expected, mDCs induced
the highest T-cell proliferation (Fig. 5 A and B). Remarkably, ADA
also induced a significant increase in CD4+ T-cell proliferation
compared to non-treated iDCs (Fig. 5 A and C). Moreover, an
enhanced proliferation of CD8+ T-cells was also observed in
cocultures with ADA-treated iDCs, although this increase was less
consistent than that of CD4+ T-cells (Fig. 5 B and C). Barely
detectable levels of CD4+ or CD8+ T-cell proliferation was
detected in autologous cocultures, neither in the absence nor in the
presence of ADA (Fig. 5 A and B), discarding the possibility of
ADA being presented as a foreign antigen. As ADA has been
previously shown capable of increasing Th-1 immune responses
when present at the immune synapse [13], we further tested
whether ADA-induced effects on iDCs could still favor this T-cell
polarization. To address this issue, co-culture supernatants were
addressed for IFN-c, IL-4, and IL-17, indicative of Th-1, Th-2
and Th-17 polarization, respectively. In all conditions tested IFN-c
levels clearly predominated, and ADA actions on iDC did not alter
this secretion profile, as we detected 423 pg/ml of IFN-c as
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a median, while only 40 pg/ml of IL-4 and 49 pg/ml of IL-17
were found (Fig. 5 D). These results indicate that the ADA-
induced effects on iDCs contribute to an improved iDC function.
ADA Increases CCR7 Expression without an Increase in
DCs Migration
To further characterize the ADA effect on DCs function, we
next tested the effect of ADA on DCs migration. CCR7 is critical
to normal DC function as it drives antigen-loaded DCs entry to
secondary-lymph nodes, through CCL19 and CCL21-dependent
chemotactic gradients [48]. CCR7 is up-regulated upon DCs
maturation, thus its expression is an indicator of DC status [43].
Therefore, we determined CCR7 expression and CCR7-de-
pendent DCs migration as a way to evaluate the DC population.
iDCs from healthy donors were cultured in the absence or in the
presence of exogenous ADA or in the presence of maturating
cocktail and CCR7 expression was determined by flow cytometry.
A small but statistically significant increase in CCR7 expression
was obtained in the presence of ADA in every tested healthy donor
(Fig. 6 A and B). In accordance with previous studies [49], the
maturation cocktail induced a more potent up-regulation of CCR7
(Fig. 6 A). We next sought to determine whether the increase on
CCR7 expression also improved CCR7-dependent DC migration.
To address this question, a transwell assay was used to assess the
migration towards CCL19 or CCL21. As expected, extremely low
numbers of iDCs migrated to CCL19 or to CCL21 after 3 hours of
assay (Fig. 6 C and D). ADA addition to iDC cultures did not
result in significant changes in iDC migration, neither to CCL19
nor to CCL21 in contrast to the migration observed with mDCs
(Fig. 6 C and D). The ADA-induced increase in CCR7 expression
fits with the role of ADA on increasing the expression of
costimulatory molecules in iDCs that confers a more mature DC
status, but is not sufficient to induce an increase on the in vitro
DCs migration.
Role of ADA in iDCs Viability
The right balance between cell death and survival is critical to
achieve a correct immune homeostasis and this is especially
important in HIV-infected donors where DCs death contributes to
the pathogenesis of the disease [50]. Thus, we next tested whether
the ADA-induced more mature DC phenotype could be playing
a role on DCs viability. iDCs from either healthy or HIV-infected
individuals were cultured in the absence or in the presence of ADA
or with maturing cocktail. DIOC6, a fluorescent dye sensing
mitochondrial potential was used to stain viable cells. Early
apoptotic and late apoptotic/necrotic cells could be easily
distinguished through the combination of low DIOC6 staining
and negative (apoptosis) or positive (necrosis) propidium iodide
staining (Fig. 7). The low percentage of cells that showed a bright
DIOC6 and positive propidium iodide staining might represent
dead cells phagocytosed by live DCs or DCs broken during
manipulation. ADA addition to iDCs from healthy or HIV-
infected donors did not result in significant changes in iDCs
viability after 48 h of cell culture as measured by low DIOC6
staining (Fig. 7 A and B). When apoptosis and necrosis were
addressed on iDCs from healthy donors, ADA was found unable
of inducing significant changes in any of these populations, (Fig. 7
A, C and D). In contrast, all HIV-infected donors showed an
increased percentage of early apoptotic cells in the presence of
ADA while a reduced necrosis was detected (Fig. 7 A, C and D).
The viability of DCs was clearly higher while reduced apoptosis
and necrosis were observed in mDCs from either healthy or HIV-
infected individuals (Fig. S4), a result most likely due to the
presence of PGE2 in the maturating cocktail [51]. These findings
indicate that ADA does not play a role in iDCs viability in healthy
individuals whereas a different situation emerges on HIV-infected
donors. In a chronic disease setting, ADA showed a protective role
against late steps of cell death, an observation which may apply to
other cells such as CD8 T-cells [52].This was however, not always
reflected in a total increase in iDCs viability, suggesting that ADA
is inhibiting a post-mitochondrial event in apoptotic cascades in
iDCs from HIV-infected individuals.
Discussion
In this study, we explored the effects of extracellular ADA on
human monocyte-derived DCs from healthy and HIV-infected
individuals. Four novel observations derive from this study. First,
ADA added to human iDCs cultures enhances DCs-self
costimulatory and maturation molecule expression. Second, we
demonstrate, for the first time, that ecto-ADA actions on iDCs are
able to increase the secretion of both pro-inflammatory cytokines
and chemokines that are known to promote Th-1 immune
responses. Third, we establish that both the enzymatic and
enzymatic-independent role of ADA participate in ADA-induced
effects. Finally, ADA globally enhances the immunogenicity of
human DCs, a process that results in an improved CD4+ and
CD8+ T-cell activation after alloantigen presentation.
Despite the now clear role of ecto-ADA on promoting an
enhanced T-cell activation, proliferation and Th-1 effector/
memory generation [13,18,21], it remained unclear whether
ecto-ADA would modulate human DC functions. It is this issue we
have investigated. Using human monocyte-derived DCs obtained
from peripheral blood, we first determined if the addition of ADA
to iDC cultures would induce the expression of costimulatory
molecules on iDCs. In fact we observed that ADA increases CD83,
CD80, CD86 and CD40 expression. These molecules are
classically considered maturation markers and their up-regulation
suggests that ADA is potentiating the DCs maturation. Consid-
ering that CD83, CD80, CD86 and CD40 are important for
delivering the appropriate secondary signals to T-cells [43,44], the
ADA-mediated up-regulation of these markers indicates that ADA
may increase the costimulatory potential of DCs. Another
interesting aspect to highlight is that the addition of ADA to
iDC cultures increases Th-1/pro-inflammatory cytokine release
including IL-12, TNF-a and IL-6. This cytokine pattern is very
similar to the ADA-increased effect on DC-T-cell autologous
cocultures [13], indicating that ADA can act not only on
lymphocytes but also on DCs to increase Th-1/pro-inflammatory
cytokine release. Whereas IL-12 is critical to polarize T-cells
towards Th-1, both IL-6 and TNF-a promote inflammation and
the activation of both innate and adaptive immune responses
including T-CD4+ memory generation [18,53] and the maturation
Figure 1. ADA enhances CD83, CD80 and CD86 expression on iDCs. iDCs, obtained as indicated in the Materials and Methods, were cultured
for 48 h in medium in the absence (2ADA) or in the presence (+ADA) of 2 mM ADA or in the presence of maturating cocktail (mDCs). Expression of
CD83 (A and B), CD80 (C and D) or CD86 (E and F) in the DCs gate was assessed by flow cytometry. In A, C and E, histogram overlays and the
percentage of positive cells (A and B) or geometric mean (C) for a representative healthy donor and HIV-infected subject are shown. In B, D and F,
values obtained from 16 to 19 healthy donors (circles) or 12 to 16 HIV-infected individuals (triangles) in the absence (open symbols) or in the
presence (filled symbols) of 2 mM ADA are plotted. Each pair of linked symbols represents results from a particular individual. *P,0.05; ***P,0.001.
doi:10.1371/journal.pone.0051287.g001
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of DCs [54]. In addition, pro-inflammatory cytokines in general
and IL-6 in particular have been shown to block Treg mediated
suppression of DCs [55] as well as global Treg suppression
capacity [56]. Together with deaminase activity, the ADA-induced
secretion of pro-inflammatory cytokines would provide a local
‘‘suppression free’’ environment to facilitate T-cell activation. In
addition to the cytokines, we also demonstrate, for the first time,
that ADA addition to iDCs culture is able to increase the secretion
of chemokines such as CXCL8, CCL2, CCL3, CCL4 and CCL5.
The global role of these chemokines is to recruit immune cells such
as neutrophils, monocytes, DCs, and activated T and B cells to the
sites where antigen processing is taking place, in order to further
develop the corresponding immune response [57].
To discern the exact mechanisms by which ADA is acting to
induce DCs maturation is difficult but our results indicate that
both the enzymatic and extraenzymatic activity of ADA are
mediating its effects. By using ADA inhibited by HgCl2 we
observed a reduced expression of costimulatory molecules and
a decreased secretion of IL-12, CCL2, CCL3 and slightly CCL4
compared to active ADA, suggesting that the enzymatic activity of
ADA is mediating part of these effects. ADA catalyzes the
irreversible deamination of adenosine to inosine and ammonia
decreasing the amount of extracellular adenosine able to bind to its
receptors. It is known that human monocyte-derived DCs as well
as plasmacytoid DCs express adenosine receptors [13,58,59] and
adenosine, by binding to its receptors, modulates DC function,
generally reducing the maturation and immunogenicity of
stimulated DCs by enhancing IL-10 while diminishing IL-12,
IL-6 and TNF-a secretion, lowering allo-stimulatory potential and
limiting Th1 polarization [58–60]. Since the ADA-induced effects
are the increase, not the decrease, of the expression or secretion of
these molecules, part of the effects observed here can be due to the
ADA-mediated reduction of adenosine available to bind adenosine
receptors. This has been seen in mice where adenosine de-
Figure 2. ADA effect on CD40 and HLA expression on iDCs. iDCs, obtained as indicated in the Materials and Methods, were cultured for 48 h
in medium in the absence (2ADA) or in the presence (+ADA) of 2 mM ADA or in the presence of maturating cocktail (mDCs). Expression of HLA-DR (A
and B), HLA-ABC (C and D) or CD40 (E and F) in the DCs gate was measured by flow cytometry. In A, C and E, histogram overlays and the geometric
mean from a representative healthy donor and HIV-infected patient are shown. In B, D and F, values obtained from 6 to 10 healthy donors (circles) or
9 to 10 HIV-infected subjects (triangles) in the absence (open symbols) or in the presence (filled symbols) of 2 mM ADA. Values obtained from 6 to 10
healthy donors (circles) or 9 to 10 HIV-infected subjects (triangles). * P,0.05.
doi:10.1371/journal.pone.0051287.g002
Figure 3. ADA increases cytokines and chemokines secretion. iDCs, obtained as indicated in the Materials and Methods, from 9 healthy
(circles) and 8 HIV-infected (triangles) donors were cultured during 48 h in medium in the absence (iDCs) or in the presence of 2 mM ADA and the
indicated cytokines and chemokines were determined in the supernatant as described in the Materials and Methods. Values are expressed as the ratio
(in-fold) of cytokine or chemokine levels obtained in the presence of ADA versus levels obtained in the absence of ADA (iDCs, the reference value of 1
is represented by a dotted line). For each group, the median is indicated by a thick line. *P,0.05; **P,0.01 with respect to iDCs.
doi:10.1371/journal.pone.0051287.g003
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amination by ecto-ADA on DCs surface was revealed to be critical
to ensure DCs activation to TLR ligands [61]. Interestingly
however, inactive ADA (ADA-Hg) is able to increase IL-6
secretion, rather than decreasing it. Since adenosine has been
proposed to signal through A2B receptors and promote IL-6
secretion on iDCs [62,63] and ADA, by binding to A2B increases
the affinity and signaling of its ligands [9], it is plausible that ADA
inactivation results in increased adenosine effects through its
receptors. We observed that part of the ADA-mediated effects are
independent of its enzymatic activity. In this respect, human or
bovine ADA binds to human CD26 [5,64,65], whereas murine
ADA neither binds to mouse nor human CD26 [66], suggesting
relevant differences between human and mice models. We have
previously described that ADA, by a mechanism independent of its
enzymatic activity, binds to CD26 on T-cells enhancing cytokine
release and T-cell costimulation [13,18,20]. To address the role of
CD26 in the ADA-induced effects, the mAb TA5.9, which is
directed against the ADA-binding epitope on CD26, was used. In
the presence of the antibody, the ADA-mediated upregulation of
CD83 and CD80 was reduced and the secretion of IL-6, CCL2
Figure 4. Enzymatic and non-enzymatic activities are implicated on ADA-mediated effects. iDCs, obtained as indicated in the Materials
and Methods, from 4 to 8 healthy donors were cultured for 48 h in medium in the absence (iDC) or in the presence of 2 mM ADA (+ADA) or 2 mM
HgCl2 inactivated ADA (ADA-Hg) or iDCs were pre-incubated with the mAb anti-CD26 TA5.9 and incubated with 2 mM ADA (ADA+TA5.9). In (A) and
(B), the expression of CD83 and CD80 was assessed in the DCs gate by flow cytometry. In C) the indicated cytokines and chemokines were
determined in the supernatants after 48 h of cell culture. Each pair of linked symbols represents results from a particular individual. Results are
expressed as the ratio (in-fold) of the values obtained in the presence of ADA, ADA-Hg or ADA+TA5.9 versus untreated cells (iDCs, the reference value
of 1 is represented by a dotted line). *P,0.05; **P,0.01 with respect to iDCs.
doi:10.1371/journal.pone.0051287.g004
Figure 5. ADA enhances DCs immunogenicity in iDC-T-cell Allogeneic cocultures. In A and B, iDCs, obtained as described in the Materials
and Methods, from a representative healthy donor were cultured during 48 h in medium in the absence of ADA (iDCs), in the presence of 2 mM ADA
(iDCs+ADA) or in the presence of maturating cocktail (mDCs). DCs were washed and cocultured with allogeneic (upper contour plots) or autologous
(lower contour plots) T-cells (1:20 DCs:T-cells ratio). After 7 days, the percentage of CD4+ (A) and CD8+ (B) T-cell proliferation was assessed by flow
cytometry using the CFSE method. In (C) percentages of CD4+ (circles) and CD8+ (squares) T-cell proliferation in the absence (open symbols) or the
presence (filled symbols) of 2 mM ADA in allogeneic cocultures from 6 to 7 healthy donors are shown. Each pair of linked symbols represents results
from a particular healthy donor. *P,0.05. In (D) bars indicate IFN-c, IL-4 and IL-17 levels in ADA-treated iDC co-culture supernatants. Results are the
mean 6 SD (pg/ml) of 3 independent experiments.
doi:10.1371/journal.pone.0051287.g005
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and CCL4 were slightly decreased suggesting a role for ADA
binding to CD26 in these effects. Membrane-bound CD26 is
known to interact with CD45 [67], a tyrosine phosphatase also
present in dendritic cells. Since CD45 has been shown to modulate
costimulatory molecule expression and TLR-induced cytokine
secretion on murine DCs [68–70] it is plausible that after ADA
binding, CD26 may interact and affect the subsequent Src kinases
under CD45.
While ecto-ADA may attract immune effector cells through
chemokine up-regulation, it clearly does not seem to promote
iDCs migration to CCL19 or CCL21 gradients, despite the
upregulated CCR7 receptor expression observed in presence of
ADA. This would fit with a role of ADA in the facilitation of DCs
maturation rather than inducing the entire process alone. Re-
gardless, the above mentioned ADA-mediated effects converge
into one ultimate purpose: render DCs more immunogenic. In
fact, in cocultures of lymphocytes and iDCs previously treated with
ADA it was observed an enhanced proliferation of CD4+ T-cells.
As DCs were extensively washed to eliminate the ADA added
before the coculture, this improved immunogenicity is likely
attributable to the enhanced expression of costimulatory molecules
previously demonstrated. It is also plausible that iDCs treated with
Figure 6. Effect of ADA on CCR7 expression and iDC migration. iDCs, obtained as described in the Materials and Methods, from healthy
donors were cultured during 48 h in medium in the absence (2ADA) or in the presence (+ADA) of 2 mM ADA or in the presence of maturating
cocktail (mDCs). In (A) and (B), CCR7 expression in the CD40+ DCs gate was measured by flow cytometry. Histogram overlays and the percentage of
CCR7 expression for a representative donor are shown in (A). Values obtained from 7 healthy donors in the absence (open symbols) or in the
presence (filled symbols) of 2 mM ADA are shown in (B). In (C) and (D), CCL19/CCL21 chemokine-induced migration assays were performed as
described in the Materials and Methods. The percentage of cell migration to CCL19 (C) or CCL21 (D) in the absence (2ADA) or in the presence (+ADA)
of 2 mM ADA or in the presence of maturating cocktail (mDCs), in relation to the initial cell input is shown. *P,0.01, ***P,0.001.
doi:10.1371/journal.pone.0051287.g006
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ADA are able to release greater amounts of cytokines and
chemokines upon T-cell contact, due to their more mature status.
Finally, we have examined the effects of ADA on dendritic cells
from asymptomatic HIV subjects. HIV-1 viral particles are known
for affecting several immune mechanisms in their compulsory
search for immune evasion. DC costimulatory molecule expression
[71] and even CD26/ADA interactions [19,20] are found to be
disrupted by HIV-1. In addition, HIV-1 deviates the appropriate
Th-1 cell polarization towards Th-2 [72] and takes advantage of
immunoregulatory mechanisms such as Tregs [73] or adenosine
cell generation [74] to ensure the disease progression. Last but not
least, diverse HIV factors are known to render DCs more sensitive
to apoptosis [50]. In the asymptomatic HIV subjects addressed
here, where limited or null viremia is found, ADA was able to
enhance costimulatory molecule expression and Th-1 promoting
cytokine/chemokine secretion, slightly enhancing DCs viability in
some individuals. Taken together, these findings suggest that HIV-
T-cell specific responses could be improved in the presence of
ADA. In fact, previous experiments revealed that inactivated HIV-
loaded DCs cocultured with autologous T-cells in the presence of
ADA enhanced HIV-specific T-cell responses [21]. In addition,
CCR5-binding chemokines CCL3, CCL4 and CCL5 are among
the most potent natural HIV-1 suppression factors [45] known to
block HIV cell fusion by antagonizing CCR5, an HIV co-receptor
[75]. Also CXCL8 showed some transcriptional inhibition of HIV-
1 in peripheral blood lymphocytes [76]. These facts raise the
question of whether ecto-ADA mediated effects on iDCs could be
accompanied of certain HIV-1-R5 suppressing activity, a hypoth-
esis deserving future investigation. Taken together, the findings
here described demonstrate that ADA enhances maturation and
costimulatory molecule expression on iDCs from healthy and
HIV-infected individuals, concomitantly to an enhanced IL-12,
IL-6, TNF-a, CXCL8, CCL3, CCL4 and CCL5 cytokine/
chemokine secretion and an altered transition to late apoptosis
in HIV-infected individuals. As a whole these effects render DCs
more immunogenic and suggest that ADA might promote
enhanced and correctly polarized HIV-specific T-cell responses
targeting asymptomatic HIV-infected individuals.
Supporting Information
Figure S1 ADA dose-response in CD80/83 expression and
cytokine secretion. iDCs, obtained as indicated in the Materials
and Methods, were cultured for 48 h in medium in the absence
(iDC) or in the presence of 1, 2, 4 or 6 mM ADA (+ADA) and the
expression of CD83 (A) or CD80 (B) was addressed by flow
Figure 7. Effect of ADA on the iDCs viability. iDCs, obtained as described in the Materials and Methods, from healthy or HIV-infected donors
were cultured during 48 h in the absence (2ADA) or in the presence (+ADA) of 2 mM ADA. Cell viability was assessed through DIOC6 and propidium
iodide (PI) staining and measured by flow cytometry. In (A), contour plots showing the percentage of viable (bright DIOC6 and negative propidium
iodide staining), apoptotic (low DIOC6 and negative propidium iodide staining) and necrotic (low DIOC6 and positive propidium iodide staining)
populations from a representative healthy or HIV-infected donor are shown. Percentage of viable (B), apoptotic (C) and necrotic (D) DCs from 7
different healthy and 6 HIV-infected donors are shown.*P,0.05.
doi:10.1371/journal.pone.0051287.g007
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cytometry in the DCs gate. Bars indicating the mean 6 SEM of 2
independent experiments are shown. In (C) the indicated cytokines
and chemokines were determined in the supernatant from iDCs
cultured in the absence (iDCs) or in the presence of 1, 2, 4 mM
ADA or in the presence of the maturating cocktail (mDCs). Bars
indicating the mean and SEM of 4 different experiments are
shown. Values are expressed as the ratio (in-fold) of CD83, CD80
or cytokine/chemokine levels obtained in the presence of ADA or
mDCs versus levels obtained in the absence of ADA (iDCs, the
reference value of 1 is represented by a dotted line).
(TIF)
Figure S2 CD80 and CD83 expression on iDCs from HIV-
infected subjects according to different clinical parameters. iDCs
from HIV-infected subjects were cultured for 48 h in medium in
the absence (2ADA) or in the presence of 2 mM ADA (+ADA)
and the expression of CD83 and CD80 was addressed by flow
cytometry. Patients were separated according to receiving
HAART or not (A), having undetectable (,DL) or detectable
viral load (.DL) (B), being above or below 600 CD4+/mL (C) or
above or below 900 CD8+/mL (D).*P,0.05, **P,0.01.
(TIF)
Figure S3 Correlation of ADA effect on CD83, CD80 and
CD86 expression on iDCs from HIV subjects with different
clinical parameters. iDCs from HIV-infected subjects were
cultured for 48 h in medium in the absence (2ADA) or in the
presence of 2 mM ADA (+ADA) and the expression of CD83,
CD80 and CD86 was addressed by flow cytometry. The % of
ADA increase on the expression of each marker was obtained by
subtracting the percentage of expression in the absence of ADA
from the the percentage of expression in the presence of ADA.
These values for CD83 (Left column), CD80 (middle column) and
CD86 (right column) were then correlated with patient’s viral load
(A), CD4+ cell counts (B), CD4+ Nadir (C) and CD8+ cell counts
(D). The Spearman correlation test was applied.
(TIF)
Figure S4 mDCs viability. iDCs, obtained as described in the
Materials and Methods, from healthy or HIV-infected donors
were cultured during 48 h in presence of a maturating cocktail
(mDCs). Cell viability was assessed through DIOC6 and
propidium Iodide (PI) staining and measured by flow cytometry.
In A, contour plots showing the percentage of viable (bright
DIOC6 and negative propidium iodide staining), apoptotic (low
DIOC6 and negative propidium iodide staining) and necrotic (low
DIOC6 and positive propidium iodide staining) populations from
a representative healthy or HIV-infected donor are shown. The
percentage of viable (B), apoptotic (C) and necrotic (D) DCs from 4
different healthy and 6 HIV-infected donors are shown.
(TIF)
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